Biotech Values

[oc631]

If Qnexa were a novel drug, I think the panel’s sentiment would have been considerably different and might well have produced a plurality of negative votes.

My question was asked in a more cynical sense. The Qnexa safety data didn't seem to merit the overwhelming panel support for the drug. Was the panels vote swayed by the data at hand? Or the idea that the drug is out there at low cost by pairing two generic compounds?